Johnson & Johnson Earnings Call Transcripts
Fiscal Year 2026
-
Strong financial growth in 2025 included a 43% share price increase and record pharmaceutical sales. All board nominees and management proposals passed, while a shareholder proposal was rejected. Strategic focus remains on innovation, portfolio strength, and disciplined capital allocation.
-
Q1 2026 saw 6.4% operational sales growth, strong performance across all segments, and raised full-year guidance. Key brands and new launches drove double-digit growth in Innovative Medicine, while MedTech and Vision showed solid momentum. Dividend increased for the 64th consecutive year.
-
A new integrated robotic surgery platform aims to transform workflow, flexibility, and efficiency in operating rooms globally, with initial U.S. launch and rapid expansion planned. The digital ecosystem Polyphonic will drive data-driven innovation, while broad procedural and geographic strategies target leadership in soft tissue and endoluminal robotics.
-
Strong growth in pharmaceuticals and MedTech, driven by innovation and strategic acquisitions, positions the company for double-digit enterprise growth. Portfolio optimization, disciplined M&A, and cost management support margin expansion, with MedTech expected to accelerate post-orthopaedics separation.
-
Entering a new growth cycle, the company expects 2026 to outperform 2025, driven by diverse innovation in medicine and MedTech. Key launches, pipeline progress, and strategic investments underpin confidence in exceeding growth targets and achieving double-digit gains by decade's end.
Fiscal Year 2025
-
Delivered strong 2025 results with 5.3% operational sales growth, robust performance across all segments, and significant R&D investment. 2026 guidance calls for 5.7%-6.7% operational sales growth, margin expansion, and continued innovation, with risks from biosimilar erosion and litigation.
-
The medtech sector is robust, with strong global leadership in electrophysiology driven by the CARTO system and rapid adoption of PFA technology. A comprehensive, expanding product portfolio and ongoing innovation in mapping, ablation, and neurovascular devices position the business for continued growth.
-
Icotrokinra is positioned as a transformative oral therapy for psoriasis and IBD, with robust efficacy, safety, and strong patient preference, targeting a 2026 launch. Tremfya continues to expand in multiple indications, while pipeline innovation and recent acquisitions aim to address unmet needs in immunology and respiratory diseases.
-
Vision care is experiencing robust growth, driven by innovation in contact lenses and intraocular lenses, global expansion, and data-driven strategies. Premiumization and integration across the patient journey are key, with AI and advanced materials supporting future growth.
-
Major advances include INLEXO's approval in bladder cancer, strong growth for RYBREVANT in lung and head and neck cancers, and CARVYKTI's long-term survival in myeloma. New launches like JNJ-2113 for psoriasis and Caplyta for depression expand the pipeline and market reach.
-
Q3 2025 saw 5.4% operational sales growth, strong double-digit gains in key brands, and robust performance in both Innovative Medicine and MedTech. The planned orthopedics separation aims to sharpen focus on high-growth areas, with full-year guidance raised and confidence in exceeding 5% revenue growth in 2026.
-
Entering a new era of growth, the business is outperforming expectations with a diversified portfolio and strong new product launches in oncology, immunology, and neuroscience. Key assets like TREMFYA, RYBREVANT, DARZALEX, and CAPLYTA are driving growth, with robust R&D and M&A strategies supporting future innovation.
-
Major product launches and pipeline advances in oncology, immunology, and neuroscience are driving confidence in exceeding growth targets through 2027. Strategic U.S. manufacturing investments, MedTech innovation, and early-stage business development underpin a robust outlook, with optimism for policy collaboration and leadership in life sciences.
-
Med tech sector growth remains robust, with innovation in AI, robotics, and personalized care driving future expansion. Portfolio shifts, strategic acquisitions, and a decentralized model are fueling above-market growth, especially in cardiovascular, surgery, and vision segments.
-
Q2 2025 saw 4.6% operational sales growth and $23.7B in revenue, with strong performance in both Innovative Medicine and MedTech. Full-year sales and EPS guidance were raised, driven by robust growth in oncology, immunology, and cardiovascular, despite STELARA headwinds.
-
The conference highlighted robust growth across immunology, oncology, and neuroscience, with key products like Tremfya, Darzalex, Carvykti, and Spravato driving momentum. Pipeline innovation and strategic launches are expected to sustain 5%-7% annual growth.
-
Strong innovation and diversification are driving growth, with robust performance in both pharmaceuticals and medtech despite biosimilar and macro headwinds. Strategic investments, new product launches, and operational efficiencies support a bullish outlook for 5-7% growth through 2030.
-
Tariff impacts have lessened, and a $55 billion U.S. investment is underway. Innovative medicine and medtech franchises are expected to deliver 5%-7% CAGR, with new products and acquisitions outperforming expectations. Legal risks are manageable, and growth is forecast to accelerate.
-
FDA regulatory processes remain stable despite leadership changes, with opportunities for AI integration. ICOTRA/KINRA shows strong efficacy and safety in immunology, while new neuroscience and oncology assets expand the pipeline. Movexion advances in large-scale AF and stroke trials.
-
The meeting highlighted strong 2024 financial results, increased dividends, and major investments in R&D and innovation. All board nominees and management proposals passed, while two shareholder proposals were not approved. Strategic focus remains on innovation, compliance, and stakeholder engagement.
-
Q1 2025 saw 4.2% operational sales growth, strong performance in both innovative medicine and MedTech, and resilience despite Stelara's LOE. Net earnings were $11B, aided by a $7B talc reserve reversal, and full-year guidance was raised. Dividend increased for the 63rd year.
-
A recent court ruling dismissed the proposed settlement plan, prompting a $7 billion reserve reversal and a return to the tort system, where the company expects continued legal success. Financial guidance through 2030 remains unchanged, and leadership is being taken to address broader mass tort and judicial reform issues.
-
Med tech end markets are expected to grow 5-7% annually through 2027, driven by innovation, increased R&D, and strategic M&A. Cardiovascular care, robotics, and portfolio optimization are key focus areas, while international growth, especially in Asia, remains a priority.
-
Long-term growth is driven by a diversified healthcare model, strategic M&A, and innovation in high-need markets. Confident in 3% growth for 2025 and 5%-7% CAGR through 2030, with new launches and acquisitions like Intra-Cellular boosting performance.
Fiscal Year 2024
-
Delivered 2024 sales of $88.8B (up 5.9%), with strong growth in Innovative Medicine and MedTech, and robust R&D and M&A investments. 2025 guidance anticipates 2.5%-3.5% operational sales growth and 8.7% adjusted EPS growth, despite biosimilar and macroeconomic headwinds.
-
Significant investments and integration in interventional cardiology are driving innovation and growth, with new clinical data and product launches for Abiomed and Shockwave. Expansion into heart failure with V-Wave and a focus on global market access position the business for continued leadership.
-
Key advances include strong uptake and survival benefit data for Rybrevant in lung cancer, high efficacy and ease of use for TAR-200 in bladder cancer, and Carvykti's leadership in myeloma with proven survival benefit and manufacturing expansion. Bispecifics Tecvayli and Talvey are poised for major growth in 2025.
-
Q3 2024 saw 6.3% operational sales growth, strong Innovative Medicine and MedTech performance, and robust R&D investment. Guidance for 2024 was raised, but headwinds in China and litigation charges impacted margins. Strategic acquisitions and pipeline progress support long-term growth.
-
Management highlighted strong growth in cardiovascular and innovation-driven investments, with a decentralized model to boost speed and accountability. Vision and orthopedics are rebounding, and new robotics launches are on track, despite ongoing China headwinds.
-
Management expressed strong confidence in meeting 2025 and long-term growth targets, driven by robust performance in innovative medicine and MedTech, strategic M&A, and a rich pipeline including oral IL-23 and TAR-200. IRA impacts are being managed through adaptive R&D strategies.
-
Q2 2024 saw 6.6% operational sales growth, strong performance in Innovative Medicine, and MedTech growth below expectations but set to accelerate in H2. Full-year EPS guidance was raised, with key pipeline milestones and major acquisitions completed.
-
The organization is leveraging its transformation into a focused healthcare entity to drive global growth, with a robust pipeline in oncology, immunology, and neuroscience. AI and data analytics are enhancing R&D and commercial efficiency, while new products like Tremfya and JNJ-2113 are positioned for significant market expansion.